Tourmaline Bio, Inc.

Ownership Transactions Reported by 27 Insiders

Symbol
TRML on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
27 West 24 Th Street, Suite 702, New York, NY

There are no Buy or Sell transactions made by insiders since 11/28/2024

Tourmaline Bio, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Novartis Ag 10%+ Owner $1.15B Oct 28, 2025
Suzanne Ildstad Director $75.2M Jun 12, 2023
Longitude Capital Partners III, LLC 10%+ Owner $54.7M May 11, 2021
Scott Requadt Former Chief Executive Officer $17.5M Jul 3, 2023
Francois Nader Director $9.08M Jun 13, 2023
Nancy Krieger Chief Medical Officer $5.61M Feb 1, 2023
Clarus Lifesciences III, L.P. 10%+ Owner $2.72M May 11, 2021
Clarus Defined Exit I, L.P. 10%+ Owner $2.72M May 11, 2021
Michael Zdanowski Chief Technology Officer $2.06M Feb 1, 2023
Mary Kay Fenton Chief Financial Officer $1.16M Jul 3, 2023
Yung H. Chyung Chief Medical Officer $966K Oct 19, 2023
Parvinder Thiara Director $0 Oct 28, 2025
Sandeep Chidambar Kulkarni CEO, Director $0 Oct 28, 2025
Caley Castelein Director $0 Oct 28, 2025
Ryan F. Robinson Cfo $0 Oct 28, 2025
Susan Dana Jones Chief Technology Officer $0 Oct 28, 2025
W. Bradford Middlekauff CBO, GC and Secretary $0 Oct 28, 2025
Mark Mcdade Director $0 Oct 28, 2025
Sapna Srivastava Director $0 Oct 28, 2025
Kevin Bruce Johnson Chief Regulatory Officer $0 Oct 28, 2025
Aaron Kantoff Director $0 Oct 28, 2025
Karen L. Smith Director Jun 13, 2023
Sandip Agarwala Director Jun 13, 2023
Gaurav Shah Director Jun 13, 2023
Geoffrey Mackay Director Jun 13, 2023
Cariad Chester Director Oct 19, 2023
Clay B. Siegall Director Oct 28, 2025

Recent Insider Transactions by Companies or Individuals for Tourmaline Bio, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.